Owkin signs licensing deal with Boehringer Ingelheim for AI drug discovery
Owkin said it signed a licensing deal with Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-related diseases.